C4X Discovery Holdings PLC
LSE:C4XD
| US |
|
Salesforce Inc
NYSE:CRM
|
Technology
|
| CL |
|
Sociedad Quimica y Minera de Chile SA
NYSE:SQM
|
Chemicals
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Centene Corp
NYSE:CNC
|
Health Care
|
| US |
|
Charles River Laboratories International Inc
NYSE:CRL
|
Life Sciences Tools & Services
|
| US |
|
Autozone Inc
NYSE:AZO
|
Retail
|
| US |
|
ServiceNow Inc
NYSE:NOW
|
Technology
|
| US |
|
Valero Energy Corp
NYSE:VLO
|
Energy
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Mosaic Co
NYSE:MOS
|
Chemicals
|
| US |
|
Roblox Corp
NYSE:RBLX
|
Media
|
| US |
|
Quanta Services Inc
NYSE:PWR
|
Construction
|
| US |
|
Albemarle Corp
NYSE:ALB
|
Chemicals
|
| US |
|
Crocs Inc
NASDAQ:CROX
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Fortinet Inc
NASDAQ:FTNT
|
Technology
|
| US |
|
Starbucks Corp
NASDAQ:SBUX
|
Hotels, Restaurants & Leisure
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.8
18.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Salesforce Inc
NYSE:CRM
|
US |
|
|
Sociedad Quimica y Minera de Chile SA
NYSE:SQM
|
CL |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Centene Corp
NYSE:CNC
|
US |
|
|
Charles River Laboratories International Inc
NYSE:CRL
|
US |
|
|
Autozone Inc
NYSE:AZO
|
US |
|
|
ServiceNow Inc
NYSE:NOW
|
US |
|
|
Valero Energy Corp
NYSE:VLO
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Mosaic Co
NYSE:MOS
|
US |
|
|
Roblox Corp
NYSE:RBLX
|
US |
|
|
Quanta Services Inc
NYSE:PWR
|
US |
|
|
Albemarle Corp
NYSE:ALB
|
US |
|
|
Crocs Inc
NASDAQ:CROX
|
US |
|
|
Fortinet Inc
NASDAQ:FTNT
|
US |
|
|
Starbucks Corp
NASDAQ:SBUX
|
US |
This alert will be permanently deleted.
C4X Discovery Holdings PLC
C4X Discovery Holdings PLC
Net Income (Common)
C4X Discovery Holdings PLC
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
C4X Discovery Holdings PLC
LSE:C4XD
|
Net Income (Common)
ÂŁ10.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Net Income (Common)
-ÂŁ154.5m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Net Income (Common)
-ÂŁ1.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genedrive PLC
LSE:GDR
|
Net Income (Common)
-ÂŁ5m
|
CAGR 3-Years
31%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-13%
|
|
|
Ergomed PLC
LSE:ERGO
|
Net Income (Common)
ÂŁ15m
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Net Income (Common)
ÂŁ17.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
C4X Discovery Holdings PLC
Glance View
C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).
See Also
What is C4X Discovery Holdings PLC's Net Income (Common)?
Net Income (Common)
10.6m
GBP
Based on the financial report for Jan 31, 2024, C4X Discovery Holdings PLC's Net Income (Common) amounts to 10.6m GBP.
You don't have any saved screeners yet
